Physician profile
Grace E Jazrawi
NPI 1720213366
$1,222.72
in general payments reported to CMS, 2019-2025
19 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $65.18 · 2021: $143 · 2022: $271 · 2023: $454 · 2024: $140 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $743.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $232.05 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $218.21 | 2022-2025 | Rexulti |
| Pfizer INC. | $128.56 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $101.02 | 2022-2023 | Eliquis |
| Glaxosmithkline, LLC. | $88.51 | 2022-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Janssen Pharmaceuticals, INC | $83.89 | 2020-2021 | |
| Exact Sciences Corporation | $74.93 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $61.41 | 2023 | |
| Lilly USA, LLC | $47.54 | 2023 | Jardiance |
| Lucid Diagnostics INC. | $23.76 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.19 | 2022 | |
| Merck Sharp & Dohme LLC | $20.91 | 2021 | |
| Bioventus LLC | $20.37 | 2023 | Durolane |
| Biohaven Pharmaceuticals, INC. | $18.95 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.57 | 2024 | Rexulti |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.41 | 2025 | Ozempic |
| Vbi Vaccine (Delaware) INC. | $17.35 | 2023 | Prehevbrio |
| Madrigal Pharmaceuticals | $15.82 | 2025 | Rezdiffra |
| Medtronic, INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grace Jazrawi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.